Monte Rosa Therapeutics, Inc. (GLUE) Dividend History

Company News

• Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer

  Monte Rosa Therapeutics presented preclinical data on its CDK2-directed molecular glue degrader, MRT-51443, which showed potential to treat HR-positive/HER2-negative breast cancer when combined with CDK4/6 inhibition and anti-estrogen therapy.

  GlobeNewswire Inc.
• Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced that its CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is developing molecular glue degrader-based medicines for various diseases.

  GlobeNewswire Inc.
• Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

  Monte Rosa Therapeutics presented preclinical data on its CDK2-directed molecular glue degrader, MRT-9643, which demonstrated the potential to provide more sustained responses in HR-positive/HER2-negative breast cancer patients when combined with current standard of care therapies, while avoiding toxicities typically associated with less selective CDK2 inhibitors.

  GlobeNewswire Inc.
• Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

  Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced that its CEO will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2024.

  GlobeNewswire Inc.
• Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

  Monte Rosa Therapeutics has initiated a Phase 1 clinical study of MRT-6160, a potent and selective VAV1-directed molecular glue degrader, for the treatment of systemic and neurological autoimmune and inflammatory diseases. The company expects to obtain initial data from the study in Q1 2025.

  GlobeNewswire Inc.